Smith, EMD;
Egbivwie, N;
Jorgensen, AL;
Ciurtin, C;
Al-Abadi, E;
Armon, K;
Bailey, K;
... Hedrich, CM; + view all
(2022)
Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study.
Clinical Immunology
, 239
, Article 109028. 10.1016/j.clim.2022.109028.
Preview |
Text
1-s2.0-S1521661622001097-main.pdf - Published Version Download (1MB) | Preview |
Abstract
BACKGROUND: In the absence of clinical trials evidence, Juvenile-onset Systemic Lupus Erythematosus (JSLE) treatment plans vary. AIM: To explore ‘real world’ treatment utilising longitudinal UK JSLE Cohort Study data. METHODS: Data collected between 07/2009–05/2020 was used to explore the choice/sequence of immunomodulating drugs from diagnosis. Multivariate logistic regression determined how organ-domain involvement (pBILAG-2004) impacted treatment choice. RESULT: 349 patients met inclusion criteria, median follow-up 4-years (IQR:2,6). Mycophenolate mofetil (MMF) was most commonly used for the majority of organ-domains, and significantly associated with renal involvement (OR:1.99, 95% CI:1.65–2.41, pc < 0.01). Analyses assessing the sequence of immunomodulators focused on 197/349 patients (meeting relevant inclusion/exclusion criteria). 10/197 (5%) solely recieved hydroxychloroquine/prednisolone, 62/197 (31%) received a single-immunomodulator, 69/197 (36%) received two, and 36/197 patients (28%) received ≥three immunomodulators. The most common first and second line immunomodulator was MMF. Rituximab was the most common third-line immunomodulator. CONCLUSIONS: Most UK JSLE patients required ≥two immunomodulators, with MMF used most commonly.
| Type: | Article |
|---|---|
| Title: | Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.clim.2022.109028 |
| Publisher version: | https://doi.org/10.1016/j.clim.2022.109028 |
| Language: | English |
| Additional information: | © 2022 The Authors. Published by Elsevier Inc. Under a Creative Commons license (https://creativecommons.org/licenses/by/4.0/). |
| Keywords: | Childhood, Immunosuppression, Juvenile-onset SLE, SLE, Treatment |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10149249 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
